PPARG and breast cancer: Based on these studies, we sought to determine if the UROtsa parent and the As3+-transformed UROtsa cell lines that are molecularly characterized as a basal subtype of BC [16] could convert to a luminal transitional cell type when treated with a PPARγ agonist and/or an EGFR inhibitor as this could affect the overall outcome of the disease.